Cannabidiol

Generic Name
Cannabidiol
Brand Names
Epidiolex, Sativex, Epidyolex
Drug Type
Small Molecule
Chemical Formula
C21H30O2
CAS Number
13956-29-1
Unique Ingredient Identifier
19GBJ60SN5
Background

Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical implications are currently being investig...

Indication

When used in combination with delta-9-tetrahydrocannabinol as the product Sativex, cannabidiol was given a standard marketing authorization (ie. a Notice of Compliance (NOC)) by Health Canada for the following indications:
...

Associated Conditions
Multiple Sclerosis, Seizures, Severe Pain, Moderate Pain
Associated Therapies
-
Clinical Trials
Related News

Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors

First Posted Date
2024-12-13
Last Posted Date
2024-12-13
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
120
Registration Number
NCT06731894
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

🇺🇸

City of Hope at Irvine Lennar, Irvine, California, United States

Relative Bioavailability of Two Orally Administered CBD Formulations in Healthy Male Adults

Phase 1
Recruiting
Conditions
Pharmacokinetics
Interventions
Drug: Cannabidiol
First Posted Date
2024-08-27
Last Posted Date
2024-08-27
Lead Sponsor
University of Saskatchewan
Target Recruit Count
20
Registration Number
NCT06574100
Locations
🇨🇦

University of Saskatchewan, Saskatoon, Saskatchewan, Canada

Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis

Phase 2
Recruiting
Conditions
Endometriosis
Interventions
Drug: Placebo
Drug: Cannabidiol
First Posted Date
2024-06-27
Last Posted Date
2024-11-20
Lead Sponsor
Mclean Hospital
Target Recruit Count
30
Registration Number
NCT06477406
Locations
🇺🇸

McLean Hospital, Belmont, Massachusetts, United States

Cannabidiol After Multi-Trauma for Pain and Opioid Therapy

Phase 2
Not yet recruiting
Conditions
Fracture
Interventions
Drug: Cannabidiol
Drug: Placebo
First Posted Date
2024-06-07
Last Posted Date
2024-08-07
Lead Sponsor
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Target Recruit Count
168
Registration Number
NCT06448923

CBD for Pain Following Orthopedic Shoulder Surgery

First Posted Date
2024-04-24
Last Posted Date
2024-10-14
Lead Sponsor
The Methodist Hospital Research Institute
Target Recruit Count
80
Registration Number
NCT06381791
Locations
🇺🇸

Houston Methodist Hospital, Houston, Texas, United States

Warrior CARE: Cannabis Behavioral Health

First Posted Date
2024-04-24
Last Posted Date
2024-07-23
Lead Sponsor
Wayne State University
Target Recruit Count
500
Registration Number
NCT06381180
Locations
🇺🇸

Wayne State University, Detroit, Michigan, United States

Study of Cannabidiol in Sanfilippo Syndrome

Phase 2
Not yet recruiting
Conditions
Sanfilippo Syndrome
Mucopolysaccharidosis III
Interventions
Drug: Placebo
Drug: Epidiolex
First Posted Date
2024-03-27
Last Posted Date
2024-10-22
Lead Sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Target Recruit Count
35
Registration Number
NCT06333041
Locations
🇺🇸

The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States

Cannabis (THC vs. CBD) in Multiple Sclerosis

Phase 2
Not yet recruiting
Conditions
Multiple Sclerosis
Interventions
Drug: THC
Drug: CBD
First Posted Date
2024-02-15
Last Posted Date
2024-02-15
Lead Sponsor
University of Calgary
Target Recruit Count
30
Registration Number
NCT06261489

MIVetsCan: Cannabidiol (CBD)-Care Trial

Phase 2
Recruiting
Conditions
Pain, Chronic
Interventions
Drug: Placebo
Drug: Cannabidiol
First Posted Date
2024-01-19
Last Posted Date
2024-03-07
Lead Sponsor
Kevin Boehnke
Target Recruit Count
468
Registration Number
NCT06213233
Locations
🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions

First Posted Date
2024-01-05
Last Posted Date
2024-04-12
Lead Sponsor
Food and Drug Administration (FDA)
Target Recruit Count
240
Registration Number
NCT06192589
Locations
🇺🇸

Spaulding Clinical Research, West Bend, Wisconsin, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy